Update on uveal melanoma: Translational research from biology to clinical practice (Review)

Andreoli MT, Mieler WF and Leiderman YI: Epidemiological trends in uveal melanoma. Br J Ophthalmol. 99:1550–1553. 2015. View Article : Google Scholar : PubMed/NCBI

Maheshwari A and Finger PT: Cancers of the eye. Cancer Metastasis Rev. 37:677–690. 2018. View Article : Google Scholar : PubMed/NCBI

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH and Nathan PD: Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol. 101:38–44. 2017. View Article : Google Scholar :

Krantz BA, Dave N, Komatsubara KM, Marr BP and Carvajal RD: Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 11:279–289. 2017. View Article : Google Scholar : PubMed/NCBI

Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, et al: An Outcome assessment of a single Institution's longitudinal experience with Uveal melanoma patients with liver metastasis. Cancers (Basel). 12:1172020. View Article : Google Scholar

Shields CL, Manalac J, Das C, Ferguson K and Shields JA: Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 25:177–185. 2014. View Article : Google Scholar : PubMed/NCBI

Shields CL, Kaliki S, Furuta M, Mashayekhi A and Shields JA: Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 32:1363–1372. 2012. View Article : Google Scholar : PubMed/NCBI

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM and Paci E; EUROCARE Working Group: Incidence of uveal melanoma in europe. Ophthalmology. 114:2309–2315. 2007. View Article : Google Scholar : PubMed/NCBI

Park SJ, Oh CM, Kim BW, Woo SJ, Cho H and Park KH: Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011). Invest Ophthalmol Vis Sci. 56:4719–4724. 2015. View Article : Google Scholar : PubMed/NCBI

Singh N, Seregard S and Singh AD: Uveal melanoma: Epidemiologic aspects. Clin Ophthalmic Oncol. 53–69. 2019. View Article : Google Scholar

Nichols EE, Richmond A and Daniels AB: Disparities in uveal melanoma: Patient characteristics. Semin Ophthalmol. 31:296–303. 2016. View Article : Google Scholar : PubMed/NCBI

Nayman T, Bostan C, Logan P and Burnier MN Jr: Uveal melanoma risk Factors: A systematic review of Meta-analyses. Curr Eye Res. 42:1085–1093. 2017. View Article : Google Scholar : PubMed/NCBI

Kaliki S, Shields CL and Shields JA: Uveal melanoma: Estimating prognosis. Indian J Ophthalmol. 63:93–102. 2015. View Article : Google Scholar : PubMed/NCBI

Al-Jamal RT and Kivelä T: Uveal melanoma among Finnish children and young adults. J AAPOS. 18:61–66. 2014. View Article : Google Scholar : PubMed/NCBI

Mallet JD, Gendron SP, Drigeard Desgarnier MC and Rochette PJ: Implication of ultraviolet light in the etiology of uveal melanoma: A review. Photochem Photobiol. 90:15–21. 2014. View Article : Google Scholar

Mishra S and Bharagava RN: Toxic and genotoxic effects of hexavalent chromium in environment and its bioremediation strategies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 34:1–32. 2016. View Article : Google Scholar

Velazquez N and Jones IS: Ocular and oculodermal melanocytosis associated with Uveal melanoma. Ophthalmology. 90:1472–1476. 1983. View Article : Google Scholar : PubMed/NCBI

Plateroti AM, Scavella V, Abdolrahimzadeh B, Plateroti R and Rahimi S: An update on oculodermal melanocytosis and rare associated conditions. Semin Ophthalmol. 32:524–528. 2017. View Article : Google Scholar

Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K, Kolbus E, et al: Iris nevus growth into melanoma: Analysis of 1611 consecutive eyes: The ABCDEF guide. Ophthalmology. 120:766–772. 2013. View Article : Google Scholar : PubMed/NCBI

Chien JL, Sioufi K, Surakiatchanukul T, Shields JA and Shields CL: Choroidal nevus: A review of prevalence, features, genetics, risks, and outcomes. Curr Opin Ophthalmol. 28:228–237. 2017. View Article : Google Scholar : PubMed/NCBI

Rodríguez A, Dueñas-Gonzalez A and Delgado-Pelayo S: Clinical presentation and management of uveal melanoma. Mol Clin Oncol. 5:675–677. 2016. View Article : Google Scholar

Nezu N, Goto H, Umazume K, Ueda S and Shibata M: Clinical analysis of uveal melanoma. Nippon Ganka Gakkai Zasshi. 121:413–418. 2017.In Japanese. PubMed/NCBI

Callender GR: Malignant melanotic tumors of the eye. A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 36:131–140. 1931.

McLean IW, Foster WD, Zimmerman LE and Gamel JW: Modifications of Callender's classification of uveal melanoma at the armed forces institute of pathology. Am J Ophthalmol. 96:502–509. 1983. View Article : Google Scholar : PubMed/NCBI

Seddon JM, Polivogianis L, Hsieh CC, Albert DM, Gamel JW and Gragoudas ES: Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol. 105:801–806. 1987. View Article : Google Scholar : PubMed/NCBI

Seregard S and Kock E: Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of Long-term survival with minimized loss to Follow-up. Acta Ophthalmol Scand. 73:340–344. 1995. View Article : Google Scholar : PubMed/NCBI

Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H and Moore KC: The morpho-logic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched Case-control study. Hum Pathol. 23:1298–1305. 1992. View Article : Google Scholar : PubMed/NCBI

Al-Jamal RT, Mäkitie T and Kivelä T: Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 44:2381–2389. 2003. View Article : Google Scholar : PubMed/NCBI

Moshari A and McLean IW: Uveal melanoma: Mean of the longest nucleoli measured on Silver-stained sections. Invest Ophthalmol Vis Sci. 42:1160–1163. 2001.PubMed/NCBI

All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ and Larsson O: Insulin-like growth Factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 43:1–8. 2002.PubMed/NCBI

Karlsson M, Boeryd B, Carstensen J, Frånlund B, Gustafsson B, Kågedal B, Sun XF and Wingren S: Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Eur J Cancer. 32A:357–362. 1996. View Article : Google Scholar : PubMed/NCBI

Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP and Jager MJ: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 52:643–650. 2011. View Article : Google Scholar

Bronkhorst IH and Jager MJ: Uveal melanoma: The inflammatory microenvironment. J Innate Immun. 4:454–462. 2012. View Article : Google Scholar : PubMed/NCBI

Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH and Jager MJ: Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 38:1865–1872. 1997.PubMed/NCBI

Onken MD, Worley LA, Ehlers JP and Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, et al: Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 32:204–220.e15. 2017. View Article : Google Scholar : PubMed/NCBI

Reichstein D: New concepts in the molecular understanding of uveal melanoma. Curr Opin Ophthalmol. 28:219–227. 2017. View Article : Google Scholar : PubMed/NCBI

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN and Harbour JW: PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 22:1234–1242. 2016. View Article : Google Scholar : PubMed/NCBI

Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S and Harbour JW: Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas. Oncotarget. 7:59209–59219. 2016. View Article : Google Scholar : PubMed/NCBI

Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG and Harbour JW: Driver mutations in uveal melanoma: Associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 134:728–733. 2016. View Article : Google Scholar : PubMed/NCBI

Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al: Development of metastatic disease after enrolment in the COMS trials for treatment of choroidal melanoma: Collaborative ocular melanoma study group report no 26. Arch Ophthalmol. 123:1639–1643. 2005. View Article : Google Scholar : PubMed/NCBI

Ramaiya KJ and Harbour JW: Current management of uveal melanoma. Expert Rev Ophthalmol. 2:939–946. 2007. View Article : Google Scholar

Pandiani C, Béranger GE, Leclerc J, Ballotti R and Bertolotto C: Focus on cutaneous and uveal melanoma specificities. Genes Dev. 31:724–743. 2017. View Article : Google Scholar : PubMed/NCBI

Ny L, Nyakas M, Hernberg M, Koivunen J, Oddershede L, Yoon MR, Wang X, Guyot P and Geisler J: BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis. J Clin Oncol. 36:e215662018. View Article : Google Scholar

Wu J, Brunner G and Celebi JT: A melanoma subtype: Uveal melanoma. J Am Acad Dermatol. 64:1185–1186. 2011. View Article : Google Scholar : PubMed/NCBI

Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A and Pringle JH: High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 111:705–710. 2004. View Article : Google Scholar : PubMed/NCBI

Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI

Van der Kooij MK, Speetjens FM, van der Burg SH and Kapiteijn E: Uveal versus cutaneous melanoma; Same origin, very distinct tumor types. Cancers (Basel). 11:8452019. View Article : Google Scholar

Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, et al: Recurrent activating mutations of G-Protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 48:675–680. 2016. View Article : Google Scholar : PubMed/NCBI

Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, et al: Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB₄. Oncotarget. 7:4624–4631. 2016. View Article : Google Scholar

Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, Maric I, Lanza F, Nasciuti F, Viaggi S, et al: Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: Detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer. 110:1058–1065. 2014. View Article : Google Scholar : PubMed/NCBI

Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI

Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U, et al: TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 109:497–501. 2013. View Article : Google Scholar : PubMed/NCBI

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

Bronkhorst IH and Jager MJ: Inflammation in uveal melanoma. Eye (Lond). 27:217–223. 2013. View Article : Google Scholar

Maat W, Ly LV, Jordanova ES, Wolff-Rouendaal D, Schalij-Delfos NE and Jager MJ: Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 49:505–510. 2008. View Article : Google Scholar : PubMed/NCBI

Mahoney KM, Freeman GJ and McDermott DF: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI

Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE and Abraham I: Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic review and Meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 5:1481–1491. 2016. View Article : Google Scholar : PubMed/NCBI

Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ and Sato T: PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 9:1323–1330. 2017. View Article : Google Scholar : PubMed/NCBI

Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S and Kiessling R: Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer. 116:2224–2233. 2010.PubMed/NCBI

Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R and Pulido JS: Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc. 107:223–228. 2009.

Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH and Jager MJ: Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 53:5370–5378. 2012. View Article : Google Scholar : PubMed/NCBI

Petralia MC, Mazzon E, Fagone P, Russo A, Longo A, Avitabile T, Nicoletti F, Reibaldi M and Basile MS: Characterization of the pathophysiological role of CD47 in Uveal melanoma. Molecules. 24:24502019. View Article : Google Scholar :

Basile MS, Mazzon E, Russo A, Mammana S, Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti F, et al: Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019. View Article : Google Scholar : PubMed/NCBI

Ding L, Lu S and Li Y: Regulation of PD-1/PD-L1 pathway in cancer by noncoding RNAs. Pathol Oncol Res. 26:651–663. 2020. View Article : Google Scholar

Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ and Sato T: PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 9:1323–1330. 2017. View Article : Google Scholar : PubMed/NCBI

Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS and Harbour JW: Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 11(496)2020. View Article : Google Scholar : PubMed/NCBI

Babchia N, Landreville S, Clément B, Coulouarn C and Mouriaux F: The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment. Exp Eye Res. 181:213–222. 2019. View Article : Google Scholar : PubMed/NCBI

Giulietti M, Vivenzio V, Piva F, Principato G, Bellantuono C and Nardi B: How much do we know about the coupling of G-proteins to serotonin receptors? Mol Brain. 7:492014. View Article : Google Scholar : PubMed/NCBI

Tschentscher F, Hüsing J, Holter T, Kruse E, Dresen IG, Jöckel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, et al: Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63:2578–2584. 2003.PubMed/NCBI

Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, Martins C, Fernandes BF and Burnier MN Jr: Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res. 14:951–956. 2008. View Article : Google Scholar : PubMed/NCBI

O'Hayre M, Degese MS and Gutkind JS: Novel insights into G protein and G Protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 27:126–135. 2014. View Article : Google Scholar : PubMed/NCBI

Liu H, Lei C, Long K, Yang X, Zhu Z, Zhang L and Liu J: Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol Rep. 34:295–301. 2015. View Article : Google Scholar : PubMed/NCBI

Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, et al: Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 25:831–845. 2014. View Article : Google Scholar : PubMed/NCBI

Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI

Coupland SE, Lake SL, Zeschnigk M and Damato BE: Molecular pathology of uveal melanoma. Eye (Lond). 27:230–242. 2013. View Article : Google Scholar

Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P and Davidorf FH: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 48:856–859. 2011. View Article : Google Scholar : PubMed/NCBI

Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW and Müller J: Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 465:243–247. 2010. View Article : Google Scholar : PubMed/NCBI

Eletr ZM and Wilkinson KD: An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys. 60:3–11. 2001. View Article : Google Scholar

He M, Chaurushiya MS, Webster JD, Kummerfeld S, Reja R, Chaudhuri S, Chen YJ, Modrusan Z, Haley B, Dugger DL, et al: Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1. Science. 364:283–285. 2019.PubMed/NCBI

Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS and Rizos H: Oncogenic signaling in uveal melanoma. Pigment Cell Melanoma Res. 31:661–672. 2018. View Article : Google Scholar : PubMed/NCBI

Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM and Harbour JW: BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 13:3712013. View Article : Google Scholar : PubMed/NCBI

Oliva M, Rullan AJ and Piulats JM: Uveal melanoma as a target for Immune therapy. Ann Transl Med. 4:1722016. View Article : Google Scholar

Szalai E, Wells JR, Ward L and Grossniklaus HE: Uveal melanoma nuclear BRCA1-associated Protein-1 immunoreactivity is an indicator of metastasis. Ophthalmology. 125:203–209. 2018. View Article : Google Scholar

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3:1122–1129. 2013. View Article : Google Scholar : PubMed/NCBI

Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S and Pfeffer U: The biology of uveal melanoma. Cancer Metastasis Rev. 36:109–140. 2017. View Article : Google Scholar : PubMed/NCBI

Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, Paridaens D, Kiliç E and de Klein A; Rotterdam Ocular Melanoma Study Group: Uveal melanomas with SF3B1 mutations: A distinct subclass associated with Late-onset metastases. Ophthalmology. 123:1118–1128. 2016. View Article : Google Scholar : PubMed/NCBI

Coltri PP, Dos Santos MGP and da Silva GHG: Splicing and cancer: Challenges and opportunities. Wiley Interdiscip Rev RNA. 10:e15272019. View Article : Google Scholar : PubMed/NCBI

Alsafadi S, Mobuchon L, Rodrigues M and Stern MH: Uveal melanoma, a model disease for splicing alterations and oncogenesis. Med Sci (Paris). 34:155–160. 2018.In French. View Article : Google Scholar

Tanaka A, Kobayashi S, Xiao M and Inoue D: Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis. Rinsho Ketsueki. 61:643–650. 2020.In Japanese.

Freemantle SJ, Spinella MJ and Dmitrovsky E: Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene. 22:7305–7315. 2003. View Article : Google Scholar : PubMed/NCBI

Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M and Bernards R: The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 122:835–847. 2005. View Article : Google Scholar : PubMed/NCBI

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, et al: EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-grade serous ovarian carcinomas. Cancer Res. 77:4268–4278. 2017. View Article : Google Scholar : PubMed/NCBI

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, et al: EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and C-MYC. Cancer Discov. 9:264–281. 2019. View Article : Google Scholar :

Bagnato A and Rosanò L: The endothelin axis in cancer. Int J Biochem Cell Biol. 40:1443–1451. 2008. View Article : Google Scholar : PubMed/NCBI

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ and Maguire JJ: Endothelin. Pharmacol Rev. 68:357–418. 2016. View Article : Google Scholar : PubMed/NCBI

Pla P, Alberti C, Solov'eva O, Pasdar M, Kunisada T and Larue L: Ednrb2 orients cell migration towards the dorsolateral neural crest pathway and promotes melanocyte differentiation. Pigment Cell Res. 18:181–187. 2005. View Article : Google Scholar : PubMed/NCBI

Smith SL, Damato BE, Scholes AG, Nunn J, Field JK and Heighway J: Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer. 87:1308–1313. 2002. View Article : Google Scholar : PubMed/NCBI

Urtatiz O and Van Raamsdonk CD: Gnaq and Gna11 in the endothelin signaling pathway and melanoma. Front Genet. 7:592016. View Article : Google Scholar : PubMed/NCBI

Mallikarjuna K, Pushparaj V, Biswas J and Krishnakumar S: Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. Curr Eye Res. 32:281–290. 2007. View Article : Google Scholar : PubMed/NCBI

Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, Losito S, La Mura A, Calemma R, Ierano C, et al: CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Front Biosci (Elite Ed). 2:13–21. 2010. View Article : Google Scholar

Vivet-Noguer R, Tarin M, Roman-Roman S and Alsafadi S: Emerging therapeutic opportunities based on current knowledge of uveal melanoma Biology. Cancers (Basel). 11:10192019. View Article : Google Scholar

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T and Aplin AE: Co-targeting HGF-CMET Signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 116:516–528. 2017. View Article : Google Scholar

Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH and Eng C: High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 24:288–295. 2006. View Article : Google Scholar

Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L and Kolb HC: The clinical importance of assessing tumor hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 21:1516–1554. 2014. View Article : Google Scholar : PubMed/NCBI

Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010. View Article : Google Scholar :

Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG and Wang B: Hypoxia inducible factor pathway inhibitors as anti-cancer therapeutics. Future Med Chem. 5:553–572. 2013. View Article : Google Scholar : PubMed/NCBI

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, et al: Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 28:135–147. 2015. View Article : Google Scholar :

Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI

Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, Merbs SL, Handa JT, Sodhi A, Bar EE and Eberhart CG: Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation. PLoS One. 9:e1053722014. View Article : Google Scholar : PubMed/NCBI

Mouriaux F, Sanschagrin F, Diorio C, Landreville S, Comoz F, Petit E, Bernaudin M, Rousseau AP, Bergeron D and Morcos M: Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 55:1277–1283. 2014. View Article : Google Scholar : PubMed/NCBI

Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, Hassan SJ, Asnaghi L, Handa JT, Merbs S, et al: Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 7:7816–7828. 2016. View Article : Google Scholar : PubMed/NCBI

Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, Ferguson JH, Yang H, Chen G, Wang B, et al: Arylsulfonamide 64B inhibits Hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clin Cancer Res. 25:2206–2218. 2019. View Article : Google Scholar :

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM and Jager MJ: Tumour angiogenesis in uveal melanoma is related to genetic evolution. Cancers (Basel). 11:9792019. View Article : Google Scholar

Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM and Jager MJ: Ischemia is related to tumour genetics in uveal melanoma. Cancers (Basel). 11:10042019. View Article : Google Scholar

Spector A: Review: Oxidative stress and disease. J Ocul Pharmacol Ther. 16:193–201. 2000. View Article : Google Scholar : PubMed/NCBI

Di Meo S, Reed TT, Venditti P and Victor VM: Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev. 2016:12450492016. View Article : Google Scholar : PubMed/NCBI

Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, et al: An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 491:449–453. 2012. View Article : Google Scholar : PubMed/NCBI

Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI

Andrisic L, Dudzik D, Barbas C, Milkovic L, Grune T and Zarkovic N: Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer. Redox Biol. 14:47–58. 2018. View Article : Google Scholar

Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ and Morrison SJ: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527:186–1891. 2015. View Article : Google Scholar : PubMed/NCBI

Dithmer M, Kirsch AM, Gräfenstein L, Wang F, Schmidt H, Coupland SE, Fuchs S, Roider J and Klettner AK: Uveal melanoma cell under oxidative Stress-influence of VEGF and VEGF-inhibitors. Klin Monbl Augenheilkd. 236:295–307. 2019.In German. View Article : Google Scholar

Costa FF: Epigenomics in cancer management. Cancer Manag Res. 2:255–265. 2010. View Article : Google Scholar : PubMed/NCBI

Yang X, Gao L and Zhang S: Comparative Pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform. 18:761–773. 2017.

Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks- Mulder A, Jager MJ and Gruis NA: Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 48:486–490. 2007. View Article : Google Scholar : PubMed/NCBI

Dammann RH, Richter AM, Jiménez AP, Woods M, Küster M and Witharana C: Impact of natural compounds on DNA methylation levels of the tumor suppressor Gene RASSF1A in cancer. Int J Mol Sci. 18:21602017. View Article : Google Scholar :

Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA and van der Velden PA: Epigenetic regulation identifies RASEF as a Tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci. 49:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI

Venza M, Visalli M, Biondo C, Lentini M, Catalano T, Teti D and Venza I: Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma. Biochim Biophys Acta. 1849:247–256. 2015. View Article : Google Scholar

Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D and Venza I: Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis Factor-related Apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun. 441:743–750. 2013. View Article : Google Scholar : PubMed/NCBI

Van der Veiden PA, Metzelaar-Blok JA, Bergman W, Hurks H, Frants RR, Gruis NA and Jager MJ: Promoter Hypermethylation: A common cause of reduced P16(INK4a) expression in uveal melanoma. Cancer Res. 61:5303–5306. 2001.

Li Y, Jia R and Ge S: Role of Epigenetics in Uveal Melanoma. Int J Biol Sci. 13:426–4332. 2017. View Article : Google Scholar : PubMed/NCBI

Yang ZK, Yang JY, Xu ZZ and Yu WH: DNA Methylation and uveal melanoma. Chin Med J (Engl). 131:845–851. 2018. View Article : Google Scholar

Audia JE and Campbell RM: Histone modifications and cancer. Cold Spring Harb Perspect Biol. 8:a0195212016. View Article : Google Scholar : PubMed/NCBI

Ding X, Wang X, Lin M, Xing Y, Ge S, Jia R, Zhang H, Fan X and Li J: PAUPAR lncRNA suppresses tumourigenesis by H3K4 demethylation in uveal melanoma. FEBS Lett. 590:1729–1738. 2016. View Article : Google Scholar : PubMed/NCBI

Dong R, Liu J, Sun W and Ping W: Comprehensive analysis of aberrantly expressed profiles of lncRNAs and miRNAs with associated ceRNA Network in lung adenocarcinoma and lung squamous cell carcinoma. Pathol Oncol Res. 26:1935–1945. 2020. View Article : Google Scholar : PubMed/NCBI

Catalanotto C, Cogoni C and Zardo G: MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci. 17:17122016. View Article : Google Scholar :

Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI

Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar

Lopez-Rincon A, Martinez-Archundia M, Martinez-Ruiz GU, Schoenhuth A and Tonda A: Automatic discovery of 100-miRNA signature for cancer classification using ensemble feature selection. BMC Bioinformatics. 20:4802019. View Article : Google Scholar : PubMed/NCBI

Li Z, Yu X, Shen J and Jiang Y: MicroRNA dysregulation in uveal melanoma: A new player enters the game. Oncotarget. 6:4562–458. 2015. View Article : Google Scholar : PubMed/NCBI

Yang C and Wei W: The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 54:351–358. 2011. View Article : Google Scholar : PubMed/NCBI

Wang YC, Yang X, Wei WB and Xu XL: Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein. Int J Ophthalmol. 11:1258–1268. 2018.

Radhakrishnan A, Badhrinarayanan N, Biswas J and Krishnakumar S: Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 15:2146–2154. 2009.PubMed/NCBI

Peng J, Liu H and Liu C: MiR-155 Promotes uveal melanoma cell proliferation and invasion by regulating NDFIP1 expression. Technol Cancer Res Treat. 16:1160–1167. 2017. View Article : Google Scholar

Li Y, Huang Q, Shi X, Jin X, Shen L, Xu X and Wei W: MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate 1. Chin Med J (Engl). 127:1410–1416. 2014.

Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, Lu F, Tu L and Qu J: MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci. 50:1559–1565. 2009. View Article : Google Scholar

Dong F and Lou D: MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 18:537–546. 2012.PubMed/NCBI

Serocki M, Bartoszewska S, Janaszak-Jasiecka A, Ochocka RJ, Collawn JF and Bartoszewski R: miRNAs regulate the HIF switch during hypoxia: A novel therapeutic target. Angiogenesis. 21:183–202. 2018. View Article : Google Scholar : PubMed/NCBI

Sun L, Wang Q, Gao X, Shi D, Mi S and Han Q: MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI

Ling J, Lu P, Zhang Y, Jiang S and Zhang Z: MiR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. Genet Mol Res. 16:gmr160390672017. View Article : Google Scholar

Liu Y, Huo Y, Wang D, Tai Y, Li J, Pang D, Zhang Y, Zhao W, Du N and Huang Y: MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. Biochem Biophys Res Commun. 50:885–892. 2018. View Article : Google Scholar

Singh AD, Turell ME and Topham AK: Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI

Kaliki S and Shields CL: Uveal melanoma: Relatively rare but deadly cancer. Eye (Lond). 31:241–257. 2017. View Article : Google Scholar

Triozzi PL and Singh AD: Blood biomarkers for uveal melanoma. Future Oncol. 8:205–215. 2012. View Article : Google Scholar : PubMed/NCBI

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY and Bidard FC: Circulating tumor cells: Clinical validity and utility. Int J Clin Oncol. 22:421–430. 2017. View Article : Google Scholar : PubMed/NCBI

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC and Marais R: Plasma total Cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 88:1–9. 2018. View Article : Google Scholar :

Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M and Sato T: Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine. 2:1821–1826. 2015. View Article : Google Scholar

Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I, et al: Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 134:1207–1213. 2014. View Article : Google Scholar

Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Thiel E, Foerster MH and Keilholz U: Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 80:57–62. 2011. View Article : Google Scholar : PubMed/NCBI

Tura A, Merz H, Reinsberg M, Lüke M, Jager MJ, Grisanti S and Lüke J: Analysis of monosomy-3 in immunomagnetically-isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res. 29:583–589. 2016. View Article : Google Scholar : PubMed/NCBI

Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD and Triozzi PL: Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 58:182–186. 2014. View Article : Google Scholar :

Russo A, Caltabiano R, Longo A, Avitabile T, Franco LM, Bonfiglio V, Puzzo L and Reibaldi M: Increased levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma. Front Pharmacol. 7:4242016. View Article : Google Scholar : PubMed/NCBI

Eldh M, Olofsson Bagge R, Lässer C, Svanvik J, Sjöstrand M, Mattsson J, Lindnér P, Choi DS, Gho YS and Lötvall J: MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer. 14:9622014. View Article : Google Scholar : PubMed/NCBI

Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, et al: Panel of Circulating MicroRNAs detects uveal melanoma with high precision. Transl Vis Sci Technol. 8:122019. View Article : Google Scholar

Peng L, Cantor DI, Huang C, Wang K, Baker MS and Nice EC: Tissue and plasma proteomics for early stage cancer detection. Mol Omics. 14:405–423. 2018. View Article : Google Scholar : PubMed/NCBI

Karimi P, Shahrokni A and Ranjbar MR: Implementation of proteomics for cancer research: Past, present, and future. Asian Pac J Cancer Prev. 15:2433–2438. 2014. View Article : Google Scholar : PubMed/NCBI

Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A and Mueller AJ: 'Melanoma inhibitory activity' (MIA): A promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 243:1161–1166. 2005. View Article : Google Scholar : PubMed/NCBI

Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R and Schaller UC: Osteopontin and 'melanoma inhibitory activity': Comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 223:239–243. 2009. View Article : Google Scholar : PubMed/NCBI

Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R and Pe'er J: Serum markers to detect metastatic uveal melanoma. Anticancer Res. 27:1897–1900. 2007.PubMed/NCBI

Missotten GS, Tang NE, Korse CM, Hurks HM, de Wolff-Rouendaal D, Keunen JE, Jager MJ and Bonfrer JM: Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 121:1117–1119. 2003. View Article : Google Scholar : PubMed/NCBI

Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, Goldinger S, Steinert HC and von Schulthess GK: Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 36:1774–1782. 2009. View Article : Google Scholar : PubMed/NCBI

Suesskind D, Schatz A, Schnichels S, Coupland SE, Lake SL, Wissinger B, Bartz-Schmidt KU and Henke-Fahle S: GDF-15: A novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 250:887–895. 2012. View Article : Google Scholar

Bande MF, Santiago M, Blanco MJ, Mera P, Capeans C, Rodríguez-Alvarez MX, Pardo M and Piñeiro A: Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. Invest Ophthalmol Vis Sci. 53:62–67. 2012. View Article : Google Scholar

Bande MF, Santiago M, Mera P, Piulats JM, Blanco MJ, Rodríguez-Álvarez MX, Capeans C, Piñeiro A and Pardo M: ME20-S as a potential biomarker for the evaluation of uveal melanoma. Invest Ophthalmol Vis Sci. 56:7007–7011. 2015. View Article : Google Scholar : PubMed/NCBI

Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, et al: Potential Role of Soluble c-Met as a New candidate biomarker of metastatic uveal melanoma. JAMA Ophthalmol. 133:1013–1021. 2015. View Article : Google Scholar : PubMed/NCBI

Angi M, Kalirai H, Prendergast S, Simpson D, Hammond DE, Madigan MC, Beynon RJ and Coupland SE: In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget. 7:49623–49635. 2016. View Article : Google Scholar : PubMed/NCBI

Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R and Singh AD: iTRAQ quantitative proteomic comparison of metastatic and non-metastatic uveal melanoma tumors. PLoS One. 10:e01355432015. View Article : Google Scholar : PubMed/NCBI

Shi XY, Li Q, Wei WB and Tao LM: Peptidome profiling of human serum of uveal melanoma patients based on magnetic bead fractionation and mass spectrometry. Int J Ophthalmol. 10:939–947. 2017.PubMed/NCBI

Song J, Merbs SL, Sokoll LJ, Chan DW and Zhang Z: A multi-plex immunoassay of serum biomarkers for the detection of uveal melanoma. Clin Proteomics. 16:102019. View Article : Google Scholar

Corrêa ZM: Assessing prognosis in uveal melanoma. Cancer Control. 23:93–98. 2016. View Article : Google Scholar : PubMed/NCBI

Balasubramanya R, Selvarajan SK, Cox M, Joshi G, Deshmukh S, Mitchell DG and O'Kane P: Imaging of ocular melanoma metastasis. Br J Radiol. 89:201600922016. View Article : Google Scholar : PubMed/NCBI

Smit KN, Jager MJ, de Klein A and Kiliç E: Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res. 75:1008002020. View Article : Google Scholar

Schopper VJ and Correa ZM: Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous. 2:42016. View Article : Google Scholar : PubMed/NCBI

Damato B, Dopierala JA and Coupland SE: Genotypic profiling of 452 choroidal melanomas with multiplex Ligation-dependent probe amplification. Clin Cancer Res. 16:6083–6092. 2010. View Article : Google Scholar : PubMed/NCBI

Dogrusöz M, Jager MJ and Damato B: Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol (Phila). 6:186–196. 2017.

Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al: Collaborative Ocular Oncology Group report number 1: Prospective validation of a Multi-gene prognostic assay in uveal melanoma. Ophthalmology. 119:1596–1603. 2012. View Article : Google Scholar : PubMed/NCBI

Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, Raynaud F, Zografos L, Schalenbourg A, Speiser D, et al: Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 99:1190–1198. 2016. View Article : Google Scholar : PubMed/NCBI

Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE and Patel SP: Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 122:2299–2312. 2016. View Article : Google Scholar : PubMed/NCBI

Frizziero L, Midena E, Trainiti S, Londei D, Bonaldi L, Bini S and Parrozzani R: Uveal melanoma biopsy: A review. Cancers (Basel). 11:10752019. View Article : Google Scholar

Erim Y, Scheel J, Breidenstein A, Metz CH, Lohmann D, Friederich HC and Tagay SP: Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: Protocol of a controlled prospective clinical observational. BMC Cancer. 16:4082016. View Article : Google Scholar

Damato B and Coupland SE: Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol. 127:423–429. 2009. View Article : Google Scholar : PubMed/NCBI

Harbour JW: Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 148:823–829.e1. 2009. View Article : Google Scholar : PubMed/NCBI

Aaberg TM Jr, Cook RW, Oelschlager K, Maetzold D, Rao PK and Mason JO III: Current clinical practice: Differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 8:2449–2460. 2014. View Article : Google Scholar

Schoenfield L, Pettay J, Tubbs RR and Singh AD: Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med. 133:1219–1222. 2009.PubMed/NCBI

Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, et al: Uveal melanoma UK national guidelines. Eur J Cancer. 51:2404–2412. 2015. View Article : Google Scholar : PubMed/NCBI

Álvarez-Rodríguez B, Latorre A, Posch C and Somoza Á: Recent advances in uveal melanoma treatment. Med Res Rev. 37:1350–1372. 2017. View Article : Google Scholar : PubMed/NCBI

Damato BE, Dukes J, Goodall H and Carvajal RD: Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 11:9712019. View Article : Google Scholar

Schank TE and Hassel JC: Immunotherapies for the treatment of uveal melanoma-history and future. Cancers (Basel). 11:10482019. View Article : Google Scholar

Bol K, van den Bosch T, Schreibelt G, Punt C, Figdor C, Paridaens D and de Vries J: Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients. J Immuno Ther Cancer:. 3:2015.

Thota R, Johnson DB and Sosman JA: Trametinib in the treatment of melanoma. Expert Opin Biol Ther. 15:735–747. 2015. View Article : Google Scholar : PubMed/NCBI

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al: Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, randomized trial (SUMIT). J Clin Oncol. 36:1232–1239. 2018. View Article : Google Scholar : PubMed/NCBI

Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, et al: New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Res. 78:542–557. 2018. View Article : Google Scholar :

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T and Aplin AE: Co-targeting HGF/cMET Signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 16:516–528. 2017. View Article : Google Scholar : PubMed/NCBI

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, et al: HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin Cancer Res. 25:5686–5701. 2019. View Article : Google Scholar

Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar :

Bonnal S, Vigevani L and Valcárcel J: The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Dis. 11:847–859. 2012. View Article : Google Scholar

Yoshimoto R, Kaida D, Furuno M, Burroughs AM, Noma S, Suzuki H, Kawamura Y, Hayashizaki Y, Mayeda A and Yoshida M: Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A. RNA. 23:47–57. 2017. View Article : Google Scholar :

Wu G, Fan L, Edmonson MN, Shaw T, Boggs K, Easton J, Rusch MC, Webb TR, Zhang J and Potter PM: Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. RNA. 24:1056–1066. 2018. View Article : Google Scholar : PubMed/NCBI

Zhou Z, Gong Q, Wang Y, Li M, Wang L, Ding H and Li P: The biological function and clinical significance of SF3B1 mutations in cancer. Biomarker Res. 8(38)2020. View Article : Google Scholar

García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R and Salazar R: A Phase 1 Trial of Oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 30:352–364. 2019. View Article : Google Scholar